Mr. Waddill has served as a member of our board of directors since July 2016. From April 2014 to December 2016, Mr. Waddill served as Senior Vice President and Chief Financial Officer, Treasurer and Secretary of Calithera Biosciences, Inc. (Nasdaq: CALA), a biotechnology company. From October 2007 to March 2014, he served as Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, Inc., a biopharmaceutical company. From October 2006 to September 2007, Mr. Waddill served as the Senior Vice President, Chief Financial Officer of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. From February 2000 to September 2006, he served as a Principal at Square One Finance, a financial consulting business. He has served as a director of Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR), a biopharmaceutical company, since January 2018 and Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company, since August 2021. Mr. Waddill received a B.S. in Accounting from the University of Illinois, Chicago, and a certification as a public accountant, which is currently inactive, after working at PricewaterhouseCoopers LLP and Deloitte LLP.
What is William D. Waddill's net worth?
The estimated net worth of William D. Waddill is at least $661.13 thousand as of February 6th, 2026. Mr. Waddill owns 7,825 shares of Protagonist Therapeutics stock worth more than $661,134 as of February 6th. This net worth evaluation does not reflect any other assets that Mr. Waddill may own. Learn More about William D. Waddill's net worth.
How do I contact William D. Waddill?
Has William D. Waddill been buying or selling shares of Protagonist Therapeutics?
During the last quarter, William D. Waddill has sold $1,673,600.00 in Protagonist Therapeutics stock. Most recently, William D. Waddill sold 20,000 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $83.68, for a transaction totalling $1,673,600.00. Following the completion of the sale, the director now directly owns 7,825 shares of the company's stock, valued at $654,796. Learn More on William D. Waddill's trading history.
Who are Protagonist Therapeutics' active insiders?
Are insiders buying or selling shares of Protagonist Therapeutics?
In the last year, insiders at the sold shares 23 times. They sold a total of 344,558 shares worth more than $24,565,743.14. The most recent insider tranaction occured on February, 6th when Director William D Waddill sold 20,000 shares worth more than $1,673,600.00. Insiders at Protagonist Therapeutics own 4.9% of the company.
Learn More about insider trades at Protagonist Therapeutics. Information on this page was last updated on 2/6/2026.
